OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Boughey on Locoregional Trials for Breast Cancer

September 27th 2015

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.

T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

September 27th 2015

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer

September 26th 2015

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Dr. Szeja on Adjuvant Radiation Therapy After Lumpectomy in Elderly Patients With TNBC

September 26th 2015

Sean Szeja, MD, radiation oncologist, University of Texas Medical Branch, discusses outcomes associated with adjuvant radiation therapy following lumpectomy for elderly patients with triple-negative breast cancer.

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

September 26th 2015

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer

September 24th 2015

Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.

Dr. Mell on Toxicities Associated With GL-ONC1 for Head and Neck Cancer

September 23rd 2015

Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell Lymphoma

September 22nd 2015

Tahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).

Jeanine Stiles on the Importance of Supportive Care for Patients With Cancer

September 22nd 2015

Jeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.

Dr. Patt on Impact of Healthcare Reform Changes on Oncology Care

September 21st 2015

Debra Patt, MD, physician, Texas Oncology, discusses the current healthcare reform changes and what effects they will have on oncology care.

Dr. Roth Compares Surgery With SBRT in Lung Cancer

September 18th 2015

Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

Dr. Carraway on Aza-Nucleoside Combinations in MDS

September 18th 2015

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

Dr. Luke Discusses Combination Approaches on Horizon in Melanoma

September 17th 2015

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Dr. Wierda on Minimal Residual Disease in CLL

September 17th 2015

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses minimal residual disease in chronic lymphocytic leukemia (CLL).Â

Dr. Sartor on Significance of Radium-223 for Community Oncologists

September 16th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

Dr. Carolyn Britten on Next Steps in Immunotherapy

September 15th 2015

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

September 15th 2015

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer

September 14th 2015

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial, which examined T-DM1 in patients with HER2-positive, HR-positive early-stage breast cancer.

Dr. Coleman on Next Steps Following ARIEL2 Trial for Ovarian Cancer

September 11th 2015

Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.

Dr. O'Connor on Targeting CD30 in DLBCL

September 10th 2015

Owen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.